Skip to main content

Nurix Therapeutics, Inc. (NRIX)

NASDAQ: NRIX · IEX Real-Time Price · USD
32.89
+0.04 (0.12%)
After-hours:Sep 24, 2021 7:49 PM EDT
32.85
-1.90 (-5.47%)
At close: Sep 24, 4:00 PM
Market Cap1.46B
Revenue (ttm)22.88M
Net Income (ttm)-89.09M
Shares Out44.43M
EPS (ttm)-2.59
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume161,523
Open34.52
Previous Close34.75
Day's Range32.84 - 34.75
52-Week Range21.53 - 52.38
Betan/a
AnalystsBuy
Price Target49.17 (+49.7%)
Est. Earnings DateOct 13, 2021

About NRIX

Nurix Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapies for the treatment of cancer and immune disorders. The company develops NX-2127, an orally available Bruton's tyrosine kinase (BTK) degrader with immunomodulatory drug (IMiD) activity for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader without IMiD activity for the treatment of relapsed or refractory B-cell malignancies; and NX-1607, an orally ava...

IndustryBiotechnology
IPO DateJul 24, 2020
Employees135
Stock ExchangeNASDAQ
Ticker SymbolNRIX
Full Company Profile

Financial Performance

In 2020, NRIX's revenue was $17.82 million, a decrease of -42.73% compared to the previous year's $31.12 million. Losses were -$43.24 million, 99.3% more than in 2019.

Financial Statements

Analyst Forecast

According to 7 analysts, the average rating for NRIX stock is "Buy." The 12-month stock price forecast is 49.17, which is an increase of 49.68% from the latest price.

Price Target
$49.17
(49.68% upside)
Analyst Consensus: Buy

News

Nurix Therapeutics Reports Second Quarter Fiscal 2021 Financial Results and Provides a Corporate Update

Initiated Phase 1 trial of lead program NX-2127 in patients with relapsed or refractory B-cell malignancies

2 months ago - GlobeNewsWire

Nurix Therapeutics Announces Appointment of Stefani A. Wolff as Chief Operating Officer and Executive Vice President,...

SAN FRANCISCO, June 21, 2021 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a biopharmaceutical company developing targeted protein modulation drugs, today announced that Stefani A. Wolff ...

3 months ago - GlobeNewsWire

Nurix Therapeutics Announces Presentation of Preclinical Data from NX-5948 Program Demonstrating Significant Reductio...

Orally available NX-5948 is a potent selective degrader of Bruton's Tyrosine Kinase (BTK) without IMiD activity

3 months ago - GlobeNewsWire

Nurix Therapeutics Appoints Industry Leader Clay Siegall, Ph.D., to its Board of Directors

SAN FRANCISCO, June 01, 2021 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a biopharmaceutical company developing targeted protein modulation drugs, today announced the appointment of Cla...

3 months ago - GlobeNewsWire

Nurix Therapeutics Announces Upcoming Presentation of NX-5948 Preclinical Data at the EULAR 2021 Virtual Congress

NX-5948, a potent selective degrader of BTK, significantly reduces inflammation in a model of autoimmune disease NX-5948, a potent selective degrader of BTK, significantly reduces inflammation in a mode...

4 months ago - GlobeNewsWire

Nurix Therapeutics to Participate in Upcoming Investor Conferences

SAN FRANCISCO, May 11, 2021 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc.  (Nasdaq: NRIX), a biopharmaceutical company developing targeted protein modulation drugs, today announced that members of Nurix ...

4 months ago - GlobeNewsWire

Nurix Therapeutics Reports First Quarter Fiscal 2021 Financial Results and Provides a Corporate Update

On track to initiate Phase 1 trials for four wholly owned drug candidates in 2021

5 months ago - GlobeNewsWire

Nurix Therapeutics Announces Participation in the 20th Annual Needham Virtual Healthcare Conference

SAN FRANCISCO, April 07, 2021 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a biopharmaceutical company developing targeted protein modulation drugs, today announced that Arthur T. Sands,...

5 months ago - GlobeNewsWire

Nurix Therapeutics Announces Collaboration for the Discovery of Novel Drugs to Treat Pediatric Cancers

Research focused on targeted degradation of MYCN for the potential treatment of neuroblastoma and medulloblastoma Program is one of four in Alex's Lemonade Stand Foundation-funded $18.5 million Crazy 8 ...

6 months ago - GlobeNewsWire

Nurix Therapeutics Announces Presentation of NX-1607 Preclinical Data at AACR

CBL-B inhibitor NX-1607 mediates anti-tumor activity through both T cells and NK cells Preclinical tumor models support clinical development of NX-1607 as monotherapy or in combination with PD-1 blockade

6 months ago - GlobeNewsWire

Nurix Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to ...

SAN FRANCISCO, March 09, 2021 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a biopharmaceutical company developing targeted protein modulation drugs, today announced the closing of its un...

6 months ago - GlobeNewsWire

Nurix Therapeutics to Participate and Present at Upcoming Investor Conferences

SAN FRANCISCO, March 09, 2021 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a biopharmaceutical company developing targeted protein modulation drugs, today announced that Arthur Sands, M....

6 months ago - GlobeNewsWire

Nurix Therapeutics Announces Pricing of Upsized Public Offering of Common Stock

SAN FRANCISCO, March 04, 2021 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a biopharmaceutical company developing targeted protein modulation drugs, today announced the pricing of its un...

6 months ago - GlobeNewsWire

Nurix Therapeutics Announces Launch of Proposed Public Offering of Common Stock

SAN FRANCISCO, March 02, 2021 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a biopharmaceutical company developing targeted protein modulation drugs, today announced that it has commenced...

6 months ago - GlobeNewsWire

Nurix Therapeutics Reports Fourth Quarter and Fiscal Year 2020 Financial Results and Provides a Corporate Update

First Investigational New Drug (IND) application cleared for NX-2127 in patients with relapsed and refractory B-cell malignancies

7 months ago - GlobeNewsWire

Nurix Therapeutics Announces Expansion of its Strategic Collaboration with Sanofi to Develop Novel Targeted Protein D...

Expansion of agreement results in an additional payment of $22 million to Nurix Expansion of agreement results in an additional payment of $22 million to Nurix

8 months ago - GlobeNewsWire

Nurix Therapeutics Presents Preclinical Data at 62nd American Society of Hematology (ASH) Annual Meeting and Exposition

Data support a planned clinical trial of NX-2127 in B-cell malignancies Data support a planned clinical trial of NX-2127 in B-cell malignancies

9 months ago - GlobeNewsWire

Nurix Therapeutics to Present at Upcoming Investor Conferences

SAN FRANCISCO, Nov. 09, 2020 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc.  (Nasdaq: NRIX), a biopharmaceutical company developing targeted protein modulation drugs, today announced that it will be prese...

10 months ago - GlobeNewsWire

Nurix Therapeutics to Present Preclinical Data at Upcoming 5th Medicinal Chemistry & Protein Degradation Summit and 6...

SAN FRANCISCO, Nov. 04, 2020 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a biopharmaceutical company developing targeted protein modulation drugs, today announced that it will present d...

10 months ago - GlobeNewsWire

Nurix Therapeutics Announces Appointment of Robert Tjian as Chairman of Scientific Advisory Board and His Resignation...

SAN FRANCISCO, Oct. 26, 2020 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), today announced that, based on his desire to lead Nurix's Scientific Advisory Board, Robert Tjian, Ph.D. has res...

10 months ago - GlobeNewsWire

Nurix Therapeutics Reports Third Quarter Fiscal 2020 Financial Results and Provides a Corporate Update

Completed recent IPO raising approximately $238 .5 million in gross proceeds

11 months ago - GlobeNewsWire

Nurix Therapeutics to Present at 3rd Annual Targeted Protein Degradation Summit

SAN FRANCISCO, Oct. 06, 2020 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc., (NASDAQ: NRIX), a company developing targeted protein modulation drugs, today announced the Company will be presenting at the 3...

11 months ago - GlobeNewsWire

Nurix Therapeutics shares slide 2.3% in trading debut

Nurix Therapeutics Inc. shares nrix fell 2.3% in their trading debut Friday, after pricing above the proposed price range.

1 year ago - Market Watch